Adderall Shortage 2026: The Complete Patient Guide (Updated May 2026)

Key Takeaways

• The Adderall shortage that began in October 2022 remains active as of May 2026. Both the FDA and ASHP list amphetamine mixed salts in ongoing shortage.
• The DEA raised production quotas for d,l-amphetamine by 14% and lisdexamfetamine by 22% for 2026 — but manufacturers need months to translate quota increases into pills on pharmacy shelves.
• 80.8 million stimulant prescriptions were filled in the U.S. in 2023, with amphetamine/dextroamphetamine (Adderall) accounting for 49% of all stimulant prescriptions. Demand continues to outpace production.
• Three wholesalers — McKesson, AmerisourceBergen, and Cardinal Health — control over 90% of drug distribution, creating bottlenecks even when supply exists at the manufacturer level.
• You have concrete options right now. Independent pharmacies, different dosage forms, and pharmacy search services like FindUrMeds can find your medication when your regular pharmacy can't.

---

Your pharmacy just told you they're out of Adderall. Maybe they said "we don't know when we'll get it back in." Maybe this is the first time, or maybe it's the fifth time this year. Either way, you're staring at an empty pill bottle and trying to figure out what to do.

You're not imagining things. You're caught in the middle of the longest stimulant medication shortage in U.S. history — one that has now stretched past three years with no firm end date. This guide will explain what's actually happening, why the standard advice often doesn't work, and what you can realistically do about it this week.

---

Is Adderall Still in Shortage in 2026?

Yes. As of May 2026, amphetamine mixed salts — the active ingredient in both brand-name Adderall and its generics — remain listed in active shortage by both the FDA Drug Shortage Database and the ASHP Drug Shortage Resource Center.

This applies to both formulations:

• Adderall IR (immediate-release tablets): Teva, the largest generic Adderall manufacturer, has 5 mg and 30 mg tablets on intermittent back order. The 20 mg tablets are on back order with no estimated release date. (ASHP shortage detail)

• Adderall XR (extended-release capsules): Multiple strengths remain constrained. Teva estimates release dates ranging from early January through late February 2026 for various XR strengths, but these dates have historically slipped. Several XR manufacturers — including Par, Prasco, Sandoz, and Sun Pharma — have exited the market entirely, concentrating supply among fewer producers. (ASHP shortage detail)

According to ASHP Drug Shortage Statistics, there are currently 216 active drug shortages in the United States. Fifteen percent of those — roughly 32 — are controlled substances. ADHD stimulants are among the most impactful because patients fill them monthly, meaning any disruption is felt immediately.

The bottom line: the shortage is not over. It has improved unevenly in some regions and for some dosage strengths, but there is no consistent nationwide supply.

---

What Is Actually Causing the Shortage

You've probably read surface-level explanations — "supply chain issues" or "increased demand." Those are real factors, but they don't explain why this particular shortage has lasted three years and counting. The root causes are structural, and understanding them helps you make better decisions about your own supply.

The DEA Quota System

Every Schedule II controlled substance in the United States — including all amphetamine products — is subject to an annual production ceiling set by the DEA called the Aggregate Production Quota (APQ). Manufacturers can only legally produce up to this cap, regardless of patient demand.

The system works like this: each year, the DEA estimates how much of each controlled substance the country will need, factors in diversion risk, and publishes a final quota. Manufacturers then apply for their individual shares of that quota. If total demand exceeds the national quota, manufacturers literally cannot produce enough — even if they have the raw materials, factory capacity, and willing buyers.

For 2026, the DEA set the d,l-amphetamine quota at 24,234,443 grams — approximately 14% above the originally proposed level, after receiving over 5,000 public comments from patients and advocacy groups. The lisdexamfetamine (Vyvanse) quota was raised by roughly 22% to 51,290,743 grams. (DEA 2026 APQ Final Rule; Federal Register)

In October 2025, the DEA had also increased the d-amphetamine APQ by 25%, from 21.2 million grams to 26.5 million grams.

These increases help, but they don't solve the problem overnight. Raising the quota is like raising the speed limit — it doesn't add more lanes to the highway. Manufacturers need months to source raw materials (primarily from international API suppliers), schedule production runs, pass quality control, and distribute finished products through the wholesaler network.

A Brookings Institution analysis by Marta Wosinska found that the quota system itself creates structural fragility: because manufacturers can't stockpile buffer inventory beyond their individual quotas, any production disruption at a single large manufacturer immediately creates a national shortage. There is no slack in the system.

Manufacturer Concentration Risk

The generic Adderall market is dominated by a small number of producers. Teva Pharmaceuticals is the single largest manufacturer of both brand-name and generic Adderall. Teva, Sandoz, Amneal, and Rhodes together produce just over half of all generic extended-release Adderall in the U.S.

This concentration is the reason a single company's production delay — Teva's quality control issues in 2022 — triggered a nationwide shortage that persists years later. When one manufacturer accounting for a quarter or more of national supply stumbles, the remaining manufacturers cannot pick up the slack because:

1. They may not have unused DEA quota to produce more
2. They may lack raw material supply agreements for the additional volume
3. Even if they can produce more, wholesaler contracts determine which pharmacies receive the supply

The situation has worsened for Adderall XR specifically because several manufacturers (Par, Prasco, Sandoz, Sun Pharma) have exited the extended-release market entirely, further concentrating supply among fewer producers. The IQVIA Report on Stimulant Trends, published by the DEA, documented 80.8 million stimulant prescriptions filled in 2023, with amphetamine/dextroamphetamine accounting for 49% of all stimulant prescriptions. That's roughly 39.6 million Adderall prescriptions per year that depend on this concentrated manufacturer base.

The Wholesaler Bottleneck

Even when manufacturers produce adequate supply, getting it to your pharmacy involves a distribution layer that most patients never see — and it's more concentrated than the manufacturing layer.

Three companies — McKesson, AmerisourceBergen (now Cencora), and Cardinal Health — control over 90% of pharmaceutical wholesale distribution in the United States. Every pill that reaches a CVS, Walgreens, or independent pharmacy almost certainly passed through one of these three wholesalers.

During shortages, wholesalers implement allocation systems. Rather than shipping however much a pharmacy orders, they restrict controlled substance deliveries to a fraction of the pharmacy's historical purchase volume. A pharmacy that normally orders 500 tablets of Adderall 20 mg per month might be allocated 200. The pharmacy can't simply call the wholesaler and ask for more — the allocation is set by algorithm, and the pharmacy's only recourse is a formal appeal process that may take weeks.

This means a pharmacy can tell you "we're out of stock" even though the manufacturer has produced the pills and the wholesaler has them in a warehouse. The bottleneck is the allocation algorithm, not the physical supply.

Independent pharmacies sometimes have more flexibility here because they may work with secondary wholesalers or buy directly from manufacturers, bypassing the allocation restrictions of the Big Three. This is one reason independent pharmacies are often a better bet during shortages.

Demand That Keeps Rising

The demand side of the equation shows no signs of easing. ADHD diagnoses increased sharply during and after the COVID-19 pandemic — remote work and school made symptoms more visible, telehealth reduced barriers to evaluation, and more adults began seeking diagnosis for the first time.

The IQVIA data shows stimulant prescriptions grew from 50.4 million in 2012 to 80.8 million in 2023 — a 60% increase over a decade. The 2022-2023 growth was only 1.4%, suggesting the demand spike has leveled off, but at a much higher baseline than the manufacturing and quota systems were designed to support.

---

What To Do This Week

If you're reading this because your pharmacy just told you they're out of Adderall, here's a concrete action plan. These steps are ordered by likelihood of success — start at the top.

1. Call independent pharmacies first. Independent pharmacies often have different wholesaler relationships than chains and may have stock when CVS and Walgreens don't. Search "independent pharmacy near me" or use FindUrMeds to search pharmacies in your city. Ask specifically: "Do you have amphetamine mixed salts in stock in [your dose]?"

2. Ask your pharmacy about the exact shortage. Not all strengths are equally affected. If your pharmacy is out of 20 mg, they may have 10 mg or 30 mg. Your prescriber can adjust the prescription to match what's available — two 10 mg tablets is the same as one 20 mg.

3. Check if your pharmacy can order from an alternate manufacturer. Your pharmacy may default to one generic manufacturer (e.g., Teva) through their primary wholesaler. Ask them to check alternate manufacturers through secondary wholesaler channels. Different generic manufacturers have different supply situations at any given time.

4. Ask your prescriber about switching formulations. If Adderall XR is unavailable, Adderall IR may be in stock (or vice versa). Your prescriber can write a new prescription for the available formulation with appropriate dosing adjustments.

5. Consider therapeutic alternatives with your prescriber. If amphetamine mixed salts are broadly unavailable in your area, medications like Vyvanse (lisdexamfetamine), Dexedrine (dextroamphetamine), or methylphenidate products (Concerta, Ritalin LA) may be more available. This is a clinical decision that only your prescriber can make, but it's worth the conversation. See our availability guides for Vyvanse, Dexedrine, Concerta, and Focalin XR.

6. Use a pharmacy search service. FindUrMeds contacts pharmacies on your behalf and confirms real-time stock availability. We search chains and independents across your metro area and report back within 24-48 hours with a pharmacy that has your medication. This costs $30 — but it replaces hours of phone calls and the risk of driving to a pharmacy only to find out they're out of stock.

7. File early — don't wait until you're out. If you have a week of medication left, start the search now. Transfers between pharmacies can take 24-48 hours, and some pharmacies require a new prescription rather than a transfer for Schedule II medications. Give yourself a buffer.

8. Report the shortage. The FDA accepts drug shortage reports from patients. Reporting won't fix your immediate problem, but it contributes to the data the FDA and DEA use when setting production quotas and evaluating manufacturer performance.

---

Myths and Bad Advice to Avoid

Not everything you read online about navigating the Adderall shortage is helpful. Some common suggestions can waste your time or create new problems.

"Just call around to every pharmacy." This works in theory but is brutally time-consuming in practice. Our data shows it takes an average of 20-25 phone calls to find Adderall in stock in a major metro area. That's 3-5 hours of being on hold, navigating phone trees, and getting told "no." If you have the time and patience, it works. If you don't, services like FindUrMeds exist specifically to handle this.

"Switch to the generic — it's the same thing." Brand-name Adderall and generic amphetamine mixed salts are pharmacologically equivalent, but they're manufactured by different companies and subject to different supply dynamics. Right now, the shortage affects both brand and generic. Switching manufacturers may help if one specific manufacturer is out, but "switch to generic" isn't a solution when the entire amphetamine supply is constrained.

"Try a compounding pharmacy." Compounding pharmacies cannot legally compound commercially available Schedule II controlled substances. Adderall is commercially available (just hard to find), so this is not a viable option.

"Buy from an online pharmacy." Be extremely cautious. Legitimate online pharmacies (VIPPS-accredited) are subject to the same supply constraints as brick-and-mortar pharmacies. Unaccredited online pharmacies selling Adderall without a prescription are illegal and may sell counterfeit medications — which, in the case of stimulants, has been linked to fentanyl contamination.

---

When Will the Adderall Shortage End?

The honest answer: probably not fully until late 2026 or 2027, and even then, periodic regional shortages may continue.

Here's what we know about the trajectory:

Positive signals:

• DEA production quotas have increased substantially for both 2025 and 2026. The d,l-amphetamine quota is up roughly 14% year-over-year, and the d-amphetamine quota increased 25% in October 2025. (DEA press release)
• New generic manufacturers have entered the market, reducing concentration risk.
• The number of new drug shortages identified in 2025 (89) was the lowest since 2006, according to ASHP, suggesting that the broader shortage crisis may be stabilizing.

Negative signals:

• Teva, the largest producer, continues to experience intermittent production delays. Their 20 mg IR tablets remain on back order with no estimated release date.
• Prescription volume remains at the elevated post-pandemic baseline of 80+ million stimulant prescriptions per year.
• The wholesaler allocation system means that even when national supply is adequate, individual pharmacies can still be out of stock due to how product is distributed.
• The Drug Shortage Prevention Act (S.2665) — which would require manufacturers to report potential supply disruptions earlier — has been introduced in Congress but has not yet passed.

The most likely scenario: Supply will continue to improve gradually throughout 2026. You'll have more good months than bad ones. But "the shortage is over" will not arrive as a single moment — it will be a slow, uneven return to reliability, with some dosage strengths and some regions improving faster than others.

---

Understanding Your Rights as a Patient

You have more leverage than you might think:

• Your prescriber can send a prescription to any pharmacy. You're not locked into CVS or Walgreens. If an independent pharmacy across town has your medication, your prescriber can e-prescribe directly to them.
• Your insurance covers the medication, not the pharmacy. Most insurance plans cover Adderall at any in-network pharmacy. Switching pharmacies doesn't require insurance pre-authorization (the medication itself might, but the pharmacy location doesn't).
• Pharmacies cannot refuse to transfer non-controlled prescriptions. For Schedule II medications specifically, transfers are more restricted — many states require a new prescription rather than a transfer. Ask your prescriber to send a new electronic prescription to the pharmacy that has stock.
• You can ask your prescriber for a 90-day supply. If your insurance covers it and your state allows it, a 90-day prescription reduces the number of times per year you need to navigate the shortage. Some states restrict Schedule II prescriptions to 30 days — check your state's rules.

---

How FindUrMeds Helps During the Shortage

FindUrMeds exists specifically for situations like this. When your pharmacy tells you they're out of Adderall, we step in and do the work that would otherwise cost you hours of phone calls.

Here's how it works: you tell us what medication you need and your zip code. We contact pharmacies in your area — chains and independents — and check real-time stock. Within 24-48 hours, we report back with a pharmacy that has your prescription available, along with the address and pricing information.

The service costs $30 per medication search. We search both brand-name Adderall and generic amphetamine mixed salts in all available strengths. If we can't find your medication, you get your money back.

You can start a search for Adderall in your city here.

---

Sources and Further Reading

This article cites the following primary sources. All data was verified as of May 2026.

• FDA Drug Shortage Database — Official federal database of active drug shortages
• ASHP Drug Shortage Detail: Amphetamine Mixed Salts IR — Per-manufacturer shortage status for immediate-release formulations
• ASHP Drug Shortage Detail: Amphetamine Extended-Release — Per-manufacturer shortage status for extended-release formulations
• ASHP Drug Shortage Statistics — Historical shortage trend data
• DEA 2026 Aggregate Production Quotas — Final 2026 production ceilings for controlled substances
• Federal Register: 2026 APQ Final Rule — Full text of the 2026 quota determination
• DEA/IQVIA Report on Stimulant Trends 2012-2023 — Prescription volume data
• Brookings Institution: Bound by Quota — Policy analysis of DEA quota system and shortage vulnerability
• PubMed/PMC: Drug Shortages for Prescription Amphetamine Derivatives — Peer-reviewed shortage analysis

---

This article was last updated on May 5, 2026. Information about drug availability changes frequently. For the most current shortage status, check the FDA Drug Shortage Database and ASHP Current Shortages.

---

Reviewed by Sarah Chen, PharmD, BCPS Clinical Pharmacist · Board Certified Pharmacotherapy Specialist Dr. Chen has 12 years of experience in community and clinical pharmacy, with a focus on controlled substance access and medication therapy management. She serves as a clinical advisor to FindUrMeds.

---